Fined $1M, Yotta Customers Still Out Millions
California's first-ever Yotta penalty is $1M, but the 18,000 California customers still waiting for Synapse restitution call it a rounding error.
Legal Desk
Hatch-Waxman, FCPA settlements, DPAs, IPR decisions. The filings that set next year's compliance guardrails before the rulemakers get there.
No filings match this filter in the first page.
Patent infringement and Hatch-Waxman litigation, False Claims Act settlements, DOJ criminal and civil investigations, FCPA enforcement, consent decrees, Deferred Prosecution Agreements, and cross-border regulator actions affecting pharma, medtech, and financial services. We follow dockets, not press releases, and flag when a filing changes the trajectory of a case.
Legal outcomes set the guardrails that compliance programs actually live by. A $350M FCPA settlement becomes the baseline for the next self-reporting calculus. An IPR decision reshapes patent strategy for every biosimilar sponsor. A DOJ dismissal under the new DAG memo signals how white-collar prosecutions will play out next year. Verdicts and settled orders move faster than rule-writing — and they bind.
Federal court litigation, DOJ criminal and civil actions, FCPA matters, and state enforcement that affects publicly traded or VC-backed companies in pharma, biotech, medtech, and financial services. We skip routine commercial disputes.
Yes — Hatch-Waxman cases, IPR decisions at the PTAB, and biosimilar BPCIA suits. We focus on decisions that change the market entry timeline for a drug or device, not procedural rulings.
Primary documents from PACER, DOJ press releases, SEC charging documents, and Deferred Prosecution Agreements filed on EDGAR. We link the underlying filings and quote the charging language directly.
No. The 483 is compliance news and analysis. Nothing published here is a substitute for counsel on a specific matter, and we don't represent parties in the cases we cover.